Premium
Phototherapy with the argon laser on human melanoma cells “sensitized” with rhodamine‐123: A new method for tumor growth inhibition
Author(s) -
Castro Dan J.,
Ward Paul H.,
Saxton Romaine E.,
Fetterman Harold R.,
Castro Donna J.
Publication year - 1988
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1288/00005537-198804000-00002
Subject(s) - in vivo , photodynamic therapy , melanoma , in vitro , rhodamine 123 , cancer research , rhodamine , laser , growth inhibition , chemistry , pathology , medicine , microbiology and biotechnology , fluorescence , biology , biochemistry , optics , physics , organic chemistry , multiple drug resistance , antibiotics
Laser photodynamic therapy of superficial malignancies is a promising new approach that will become clinically useful when fluorochromes with high tumor specificity and low toxicity to normal tissues are identified. We recently reported that the mitochondrial dye, Rhodamine‐123 (Rh‐123), at nontoxic doses, is an effective sensitizing agent for argon laser treatment of human squamous carcinoma and melanoma cells in vitro. We now report the complete inhibition of in vivo tumor development by human M24 melanoma cells transplanted subcutaneously into nu/nu mice after exposure to 1μg/ml of Rh‐123 for 1 hour and treatment with an argon laser at nonthermal temperatures of 38 to 40 °C. Significant in vivo growth was observed for all control tumors. These results demonstrate that Rh‐123 enhances the tumoricidal effects of the argon laser at nonthermal temperatures and provides evidence that effective photodynamic therapy may be possible in vivo with the new fluorochrome Rhodamine‐123.